| MeSH term | MeSH ID | Detail |
|---|---|---|
| Erythema Nodosum | D004893 | 5 associated lipids |
| Hand Dermatoses | D006229 | 5 associated lipids |
| Desulfovibrionaceae Infections | D045824 | 5 associated lipids |
| Rickettsia Infections | D012282 | 5 associated lipids |
| Splenic Diseases | D013158 | 5 associated lipids |
| Boutonneuse Fever | D001907 | 5 associated lipids |
| Sexually Transmitted Diseases, Bacterial | D015231 | 5 associated lipids |
| Ureaplasma Infections | D016869 | 5 associated lipids |
| Nocardia Infections | D009617 | 6 associated lipids |
| Bronchitis | D001991 | 6 associated lipids |
clarithromycin
clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
Cross Reference
Introduction
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with clarithromycin?
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (63)
- J. Antimicrob. Chemother. (56)
- J. Clin. Microbiol. (39)
- Others (258)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with clarithromycin
PubChem Associated disorders and diseases
What pathways are associated with clarithromycin
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with clarithromycin?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- J. Antimicrob. Chemother. (25)
- Antimicrob. Agents Chemother. (20)
- J. Clin. Microbiol. (9)
- Others (66)
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with clarithromycin?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with clarithromycin?
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (5)
- Drug Metab. Dispos. (1)
- FEMS Immunol. Med. Microbiol. (1)
- Others (5)
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with clarithromycin?
Related references are published most in these journals:
- J. Antimicrob. Chemother. (20)
- Antimicrob. Agents Chemother. (17)
- J. Clin. Microbiol. (13)
- Others (57)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with clarithromycin?
Mouse Model
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with clarithromycin
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Ives DV et al. | Impact of clarithromycin and azithromycin on patterns of treatment and survival among AIDS patients with disseminated Mycobacterium avium complex. | 1995 | AIDS | pmid:7755914 |
| Fichtenbaum CJ et al. | Reply to 'Possible bias of ascertainment in assessing chemoprophylaxis for cryptosporidiosis' by Holmberg and Moorman. | 2001 | AIDS | pmid:11546956 |
| Holmberg SD and Moorman AC | Possible bias of ascertainment in assessing chemoprophylaxis for cryptosporidiosis. | 2001 | AIDS | pmid:11504998 |
| Chaisson RE et al. | Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic Mycobacterium avium complex disease in patients with HIV infection. | 1997 | AIDS | pmid:9147422 |
| MacÃas J et al. | Rhodococcus or mycobacterium? An example of misdiagnosis in HIV infection. | 1997 | AIDS | pmid:9030376 |
| Hewitt RG et al. | Prevention of disseminated Mycobacterium avium complex infection with reduced dose clarithromycin in patients with advanced HIV disease. | 1999 | AIDS | pmid:10449290 |
| Bayoumi AM and Redelmeier DA | Preventing Mycobacterium avium complex in patients who are using protease inhibitors: a cost-effectiveness analysis. | 1998 | AIDS | pmid:9727572 |
| Fichtenbaum CJ et al. | Rifabutin but not clarithromycin prevents cryptosporidiosis in persons with advanced HIV infection. | 2000 | AIDS | pmid:11153670 |
| High-dose clarithromycin should be avoided. | 1996 | AIDS Alert | pmid:11363723 | |
| Physician's aggressive preventive therapy differs. | 1995 | AIDS Alert | pmid:11362774 | |
| New drug applications sought. | 1995 | AIDS Alert | pmid:11362777 | |
| Researchers find new drugs to fight MAC. | 1995 | AIDS Alert | pmid:11362925 | |
| Clarithromycin for MAC. | 1995 | AIDS Patient Care | pmid:11361361 | |
| Rosales CM et al. | AIDS presenting with cutaneous Kaposi's sarcoma and bacillary angiomatosis in the bone marrow mimicking Kaposi's sarcoma. | 2002 | AIDS Patient Care STDS | pmid:12542930 |
| Mah Ming JB and Gill MJ | Drug-induced rhabdomyolysis after concomitant use of clarithromycin, atorvastatin, and lopinavir/ritonavir in a patient with HIV. | 2003 | AIDS Patient Care STDS | pmid:12816614 |
| Monno R et al. | Chlamydia trachomatis and Mycobacterium tuberculosis lung infection in an HIV-positive homosexual man. | 2001 | AIDS Patient Care STDS | pmid:11788074 |
| Yangco BG et al. | Is primary mycobacterium avium complex prophylaxis necessary in patients with CD4 <50 cells/μL who are virologically suppressed on cART? | 2014 | AIDS Patient Care STDS | pmid:24833016 |
| Desimone JA et al. | Treatment of Mycobacterium avium complex immune reconstitution disease in HIV-1-infected individuals. | 2003 | AIDS Patient Care STDS | pmid:14746655 |
| NIAID study rules out high-dose clarithromycin for AIDS-related MAC. | 1996 | AIDS Patient Care STDS | pmid:11361534 | |
| New data suggest antibiotic clarithromycin is effective in prolonging life of AIDS patients. | 1996 | AIDS Patient Care STDS | pmid:11361575 | |
| Clarithromycin and MAC. | 1996 | AIDS Patient Care STDS | pmid:11361673 | |
| Different clarithromycin doses affect mortality. | 1997 | AIDS Patient Care STDS | pmid:11361754 | |
| Aboulafia DM | Thalidomide-based treatment for HIV-associated multiple myeloma: a case report. | 2003 | AIDS Read | pmid:14524324 |
| Kahlon SS et al. | Mycobacterium-avium-intracellulare complex immune reconstitution inflammatory syndrome in HIV/AIDS presenting as osteomyelitis. | 2008 | AIDS Read | pmid:18975441 |
| Chu J et al. | Drug efficacy by direct and adjusted indirect comparison to placebo: An illustration by Mycobacterium avium complex prophylaxis in HIV. | 2011 | AIDS Res Ther | pmid:21388558 |
| Smibert OC et al. | Short Communication: Mycobacterium avium Complex Infection and Immune Reconstitution Inflammatory Syndrome Remain a Challenge in the Era of Effective Antiretroviral Therapy. | 2017 | AIDS Res. Hum. Retroviruses | pmid:28791872 |
| Pilotto A et al. | Cure of Helicobacter pylori infection in elderly patients: comparison of low versus high doses of clarithromycin in combination with amoxicillin and pantoprazole. | 2001 | Aliment. Pharmacol. Ther. | pmid:11421879 |
| Tepes B et al. | Is a one-week course of triple anti-Helicobacter pylori therapy sufficient to control active duodenal ulcer? | 2001 | Aliment. Pharmacol. Ther. | pmid:11421880 |
| Calvet X et al. | What is the optimal length of proton pump inhibitor-based triple therapies for H. pylori? A cost-effectiveness analysis. | 2001 | Aliment. Pharmacol. Ther. | pmid:11421884 |
| Huang J et al. | Randomised controlled trial: sequential vs. standard triple therapy for Helicobacter pylori infection in Chinese children-a multicentre, open-labelled study. | 2013 | Aliment. Pharmacol. Ther. | pmid:24117692 |
| Chacko Y and Holtmann GJ | Helicobacter pylori eradication and weight gain: has it opened a Pandora's box? | 2011 | Aliment. Pharmacol. Ther. | pmid:21679208 |
| Zullo A et al. | High rate of Helicobacter pylori eradication with sequential therapy in elderly patients with peptic ulcer: a prospective controlled study. | 2005 | Aliment. Pharmacol. Ther. | pmid:15948808 |
| Logan RP et al. | Eradication of Helicobacter pylori and prevention of recurrence of duodenal ulcer: a randomized, double-blind, multi-centre trial of omeprazole with or without clarithromycin. | 1995 | Aliment. Pharmacol. Ther. | pmid:8527618 |
| Harb AH et al. | Systematic review and meta-analysis: full- vs. half-dose anti-microbials in clarithromycin-based regimens for Helicobacter pylori eradication. | 2015 | Aliment. Pharmacol. Ther. | pmid:26011564 |
| Pipkin GA et al. | Review article: one-week clarithromycin triple therapy regimens for eradication of Helicobacter pylori. | 1998 | Aliment. Pharmacol. Ther. | pmid:9768524 |
| Louw JA et al. | Helicobacter pylori eradication and ulcer healing with daily lansoprazole, plus 1 or 2 weeks co-therapy with amoxycillin and clarithromycin. | 1998 | Aliment. Pharmacol. Ther. | pmid:9768531 |
| Laine L et al. | Low rate of emergence of clarithromycin-resistant Helicobacter pylori with amoxycillin co-therapy. | 1998 | Aliment. Pharmacol. Ther. | pmid:9768532 |
| Di Caro S et al. | Mono, dual and triple moxifloxacin-based therapies for Helicobacter pylori eradication. | 2002 | Aliment. Pharmacol. Ther. | pmid:11876707 |
| Wu JC et al. | Effect of Helicobacter pylori eradication on oesophageal acid exposure in patients with reflux oesophagitis. | 2002 | Aliment. Pharmacol. Ther. | pmid:11876709 |
| Goddard AF et al. | Randomized controlled comparison of nitroimidazoles for the eradication of Helicobacter pylori and relief of ulcer-associated and non-ulcer dyspepsia. | 1999 | Aliment. Pharmacol. Ther. | pmid:10233187 |
| Kolkman JJ et al. | Ranitidine bismuth citrate with clarithromycin versus omeprazole with amoxycillin in the cure of Helicobacter pylori infection. | 1997 | Aliment. Pharmacol. Ther. | pmid:9663840 |
| Miyaji H et al. | Susceptibility of Helicobacter pylori isolates to metronidazole, clarithromycin and amoxycillin in vitro and in clinical treatment in Japan. | 1997 | Aliment. Pharmacol. Ther. | pmid:9663841 |
| Iijima K et al. | Long-term effect of Helicobacter pylori eradication on the reversibility of acid secretion in profound hypochlorhydria. | 2004 | Aliment. Pharmacol. Ther. | pmid:15153171 |
| Cammarota G et al. | High efficacy of 1-week doxycycline- and amoxicillin-based quadruple regimen in a culture-guided, third-line treatment approach for Helicobacter pylori infection. | 2004 | Aliment. Pharmacol. Ther. | pmid:15043520 |
| Fraser AG | Editorial: replacing standard proton pump inhibitors with vonoprazan may breathe new life into triple therapy for Helicobacter pylori. | 2017 | Aliment. Pharmacol. Ther. | pmid:28776748 |
| Jung YS et al. | Editorial: replacing standard proton pump inhibitors with vonoprazan may breathe new life into triple therapy for Helicobacter pylori-authors' reply. | 2017 | Aliment. Pharmacol. Ther. | pmid:28776746 |
| Sheu BS et al. | Esomeprazole 40 mg twice daily in triple therapy and the efficacy of Helicobacter pylori eradication related to CYP2C19 metabolism. | 2005 | Aliment. Pharmacol. Ther. | pmid:15691303 |
| Wong WM et al. | Lansoprazole, levofloxacin and amoxicillin triple therapy vs. quadruple therapy as second-line treatment of resistant Helicobacter pylori infection. | 2006 | Aliment. Pharmacol. Ther. | pmid:16423001 |
| Lim AG et al. | Helicobacter pylori eradication using a 7-day regimen of low-dose clarithromycin, lansoprazole and amoxycillin. | 1997 | Aliment. Pharmacol. Ther. | pmid:9218079 |
| Zullo A et al. | Clarithromycin or levofloxacin in the sequential therapy for H. pylori eradication? | 2010 | Aliment. Pharmacol. Ther. | pmid:20518756 |